From GlobeNewswire.: 2025-03-13 07:00:00

AC Immune reported full-year 2024 financial results, highlighted by a $100 million upfront payment from a landmark exclusive option and license deal with Takeda for ACI-24.060. Positive interim safety data was shown in Down syndrome and Alzheimer’s disease cohorts, while JNJ-2056 received FDA Fast Track Designation in Alzheimer’s. Cash resources at year-end were CHF 165.5 million, allowing funding into Q1 2027.

AC Immune’s CEO, Dr. Andrea Pfeifer, emphasized the company’s progress in 2024, including key partnerships and clinical advancements. The Takeda deal for ACI-24.060 involves potential milestone payments up to $2.1 billion, strengthening AC Immune’s pipeline. The company’s innovation and achievements underscore the potential for precision prevention of neurodegenerative diseases.

The company made significant strides in its active immunotherapy programs, such as the positive interim data from the ABATE Phase 1b/2 trial for ACI-24.060 and the milestone payment triggered by the JNJ-2056 ReTain Phase 2b trial. ACI-7104.056 also showed promising results in the VacSYn Phase 2 trial for Parkinson’s disease, with no significant safety concerns reported.

AC Immune’s small molecule programs, including NLRP3 and Tau inhibitors, are progressing towards lead candidate selection with anticipated results in 2025. Diagnostic programs, like the FDA Fast Track Designation for the Tau PET diagnostic PI-2620, are advancing, along with innovative presentations and developments in disease diagnosis and treatment at industry conferences.

The company’s dedication to advancing precision therapeutics for neurodegenerative diseases was evident in 2024, with promising clinical data, key partnerships, and innovative developments. The financial strength, strategic collaborations, and progress across various programs position AC Immune for continued success in reshaping the treatment landscape for devastating conditions like Alzheimer’s and Parkinson’s diseases. morADC has high potential in combating neurodegeneration by combining Morphomers® with SupraAntigen® monoclonal antibodies. Milestones for 2025 include ACI-24.060 ABATE Phase 2 trial results, TDP-43 monoclonal antibody progress, and more. Financially, the company reported a cash position of CHF 165.5 million in 2024, with significant contract revenues and R&D expenses.

For 2025, AC Immune SA expects total cash expenditure to be in the range of CHF 75-85 million. The company is a leader in precision prevention for neurodegenerative diseases, with a pipeline of therapeutic and diagnostic programs. Strategic partnerships have provided substantial funding for their proprietary programs.

AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases. Their SupraAntigen® and Morphomer® technologies drive a diverse pipeline of assets. The company has secured strategic partnerships with global pharmaceutical companies and has a strong track record of advancing their programs. AC Immune’s financial report for 2024 shows total assets of CHF 230,913, with non-current assets at CHF 58,919 and current assets at CHF 171,994. Shareholders’ equity stands at CHF 112,270 while liabilities total CHF 118,643. The company reported an operating loss of CHF 52,378 and a loss per share of CHF 0.51.

In 2024, AC Immune recorded revenue of CHF 27,309, a significant increase from previous years. Operating expenses totaled CHF 79,687, resulting in an operating loss of CHF 52,378. The company reported a loss before tax of CHF 50,913 and a loss per share of CHF 0.51 for the year.

The consolidated statements of comprehensive income for 2024 show a total comprehensive loss of CHF 53,954. This includes items that may be reclassified to income or loss in subsequent periods, such as currency translation differences. Additionally, other items that will not be reclassified to income or loss resulted in a total comprehensive loss of CHF 3,038.



Read more at GlobeNewswire.:: AC Immune Reports Full Year 2024 Financial Results and